Clayton Hardman states, “It is the inherent nature to want to grow, and we feel this will produce additional revenues and resources for the company. We are at a point that we are able to seek out acquisitions with significant capital in place. We are looking at 6 companies currently in which Southbridge will be able to help us acquire. These additional companies will bring additional potential revenue of $15,000,000 or greater and EBITDA greater than 20% through acquisitions in 2008. Funding for the acquisitions is in place.”
Southbridge is currently in negotiations with three companies that bring complementary medical capabilities into Biomagnetics with excellent EBITDA ratios to revenue. Southbridge anticipates the execution of letters of intent in the immediate future.
About Biomagnetics Diagnostics Corporation
Biomagnetics Diagnostics Corporation, through its wholly owned subsidiary, Biospectrum Technologies, Inc. is a company that has patented revolutionary diagnostic equipment and highly specific and sensitive assays that are designed to be qualitative, (yes/no) and quantitative (viral load/degree of infection), easily performed and cost effective.
www.biomagneticsbmgp.com
About Southbridge Business Resources
A private management group formed in 1990 that offers innovative business solutions to both privately held and publicly held firms. Southbridge has primary focus in merger & acquisition, capital procurement and management implementation.
www.sbri.biz
Forward Looking Statement:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performances of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
Contact:
Biomagnetics Diagnostics Corp Paul Hardman, 916-987-7078
Source: Biomagnetics Diagnostics Corp.
